Novo Nordisk to boost US diabetes sales force by 60%

Share this article:
Danish drugmaker Novo Nordisk announced plans to boost the size of its US diabetes care sales force by 60%, or 700 reps, before mid-2007. Novo Nordisk controls approximately 40% of the US insulin market, which has grown increasingly competitive over the past two years following the launches of Lilly and Amylin’s GLP-1 inhibitor Byetta, Pfizer’s Exubera inhaled insulin and Merck’s DPP-4 inhibitor Januvia. Novo Nordisk said the goal of its field force expansion is to further support its currently marketed insulin analogs—Levemir, NovoLog Mix 70/30 and NovoLog—and gear up for the planned 2009 launch of its Liraglutide diabetes treatment. Analysts said the Novo sales force increase is a defensive move to help the company compete with Januvia, Exubera and Novartis’ yet-to-be approved Galvus. Poul la Cour, an analyst with Carnegie Bank, told United Press International that other companies won’t raise their sales force levels as a response. “That’s because their competitors…already have more sales reps than Novo. Eli Lilly might increase to support Byetta…But so far, that launch has been incredible, so they'll only increase if there's a slow-down.”
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...